Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Theratechnologies

< Previous 1 2 3 Next >
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Provides Update on Sale Process
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies CROI Presentation Highlights Limitations of Using BMI to Assess Cardiovascular (CV) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Resumes Distribution of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Provides Update on EGRIFTA SV® Supply
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1b, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Resumed Production of EGRIFTA SV®
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Secures up to $75 Million in New Credit Facilities with TD Bank and Investissement Québec
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present at Upcoming Investor Conferences in September
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.